Drug Non-Adherence And Reasons Among Multidrug-Resistant Tuberculosis Patients In Guizhou, China: A Cross-Sectional Study

References

• World Health Organization. Global Tuberculosis Report, 2018. Geneva: WHO/CDS/TB/2018.20 Geneva, Switzerland: WHO; 2018.
   Google Scholar
• World Health Organization. Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-resistant Tuberculosis. Geneva: WHO/HTM/TB/2014.11 Geneva, Switzerland: WHO; 2014.
   Google Scholar
• Podewils LJ, Gler MTS, Quelapio MI, Chen MP. Patterns of treatment interruption among patients with multidrug-resistant TB (MDR TB) and association with interim and final treatment outcomes. PLoS One. 2013;8(7):e70064. doi:10.1371/journal.pone.007006423922904
   PubMed Web of Science ®Google Scholar
• Bastard M, Sanchez-Padilla E, Hewison C, et al. Effects of treatment interruption patterns on treatment success among patients with multidrug-resistant tuberculosis in Armenia and Abkhazia. J Infect Dis. 2015;211(10):1607–1615. doi:10.1093/infdis/jiu55125312040
   PubMed Web of Science ®Google Scholar
• Yin J, Wang XM, Zhou L, Wei XL. The relationship between social support, treatment interruption and treatment outcome in patients with multidrug-resistant tuberculosis in China: a mixed-methods study. Trop Med Int Health. 2018;23(6):668–677. doi:10.1111/tmi.1308429691959
   PubMed Web of Science ®Google Scholar
• Xl W, Yin J, Gy Z, et al. Treatment interruption and directly observed treatment of multidrug-resistant tuberculosis patients in China. Int J Tuberc Lung Dis. 2015;19(4):413–419.25859996
   PubMed Web of Science ®Google Scholar
• Schaefer MR, Wagoner ST, Young ME, et al. Subjective versus objective measures of medication adherence in adolescents/young adults with attention-deficit hyperactivity disorder. J Dev Behavior Pediatr. 2019;40(1):54–59. doi:10.1097/DBP.0000000000000602
   PubMed Web of Science ®Google Scholar
• Cheng SM. Current situation and recommendation of MDR-TB prevention and control in China. Chin Trop Med. 2017;17(3):213–215.
   Google Scholar
• Guizhou provincial health and family planning commission. Guizhou provincial TB control programme from 2016 to 2020. Document no. 55. Available from: http://www.chinatb.org/xxjlg/201712/P020171217473860262138.pdf. Accessed 913, 2019
   Google Scholar
• Chen W, Lei SG, Li Y, An Z, Yang L. Analysis on implementation effect of MDR-TB global fund in Guizhou Province. China Health Care Nutr. 2014;07:3716.
   Google Scholar
• Wang Y, Wang LX, Xu SF, et al. Treatment for MDR-TB. National Handbook for MDR-TB Control and Management, 2012. Li X. Beijing, China: Military Medical Science Press; 2012:16–18.
   Google Scholar
• National essential drugs list issued by National Health Commission of the People’s Republic of China in 2018. Available from: http://www.nhc.gov.cn/ewebeditor/uploadfile/2018/10/20181025195256627.pdf. Accessed 913, 2019.
   Google Scholar
• The list of medicines for national basic medical insurance, industrial injury insurance and maternity insurance. Available from: http://www.nhsa.gov.cn/art/2019/8/20/art_37_1666.html. Accessed 913, 2019
   Google Scholar
• Guide price list of national essential drugs issued by national development and reform commission in 2009. Available from: http://jgs.ndrc.gov.cn/zcfg/200910/t20091002_748502.html. Accessed 913, 2019.
   Google Scholar
• Policy interpretation of the work plan for adjusting the national directory of insured drugs in 2019. Available from: http://www.nhsa.gov.cn/art/2019/4/17/art_38_1212.html. Accessed 913, 2019
   Google Scholar
• Liang LL, Langenbrunner JC. The Long March to Universal Coverage: Lessons from China. Washington (DC): The World Bank; 1 2013 Universal Health Coverage Studies Series (UNICO) UNICO Studies Series No. 9.
   Google Scholar
• Wang LX, Xu CH, Zhao J, Chen C, Li RZ, Chen MT. Budget calculation on management of the national standard for multi-drug resistant tuberculosis. Chin Health Resour. 2011;14(4):250–253.
   Google Scholar
• Chongsuvivatwong V. Analysis of Epidemiological Data Using R and Epicalc. second ed. Thailand: Epidemiology Unit Prince of Songkla University; 2012.
   Google Scholar
• Bloss E, Kuksa L, Holtz TH, et al. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000–2004. Int J Tuberc Lung Dis. 2010;14(3):275–281.20132617
   PubMed Web of Science ®Google Scholar
• Wu S, Zhang Y, Sun F, et al. Adverse events associated with the treatment of multidrug-resistant tuberculosis: a systematic review and meta-analysis. Am J Ther. 2016;23(2):e521–e530. doi:10.1097/01.mjt.0000433951.09030.5a24284652
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wu SS, Xia YY, et al. adverse events associated with treatment of multidrug-resistant tuberculosis in China: an ambispective cohort study. Med Sci Monit. 2017;18(23):2348–2356. doi:10.12659/MSM.904682
   Web of Science ®Google Scholar
• Carroll MW, Lee M, Cai Y, et al. Frequency of adverse reactions to first- and second-line anti-tuberculosis chemotherapy in a Korean cohort. Int J Tuberc Lung Dis. 2012;16(7):961–966. doi:10.5588/ijtld.11.0044-e22584241
   PubMed Web of Science ®Google Scholar
• Sturdy A, Goodman A, Jose RJ, et al. Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. J Antimicrob Chemother. 2011;66(8):1815–1820. doi:10.1093/jac/dkr22121642291
   PubMed Web of Science ®Google Scholar
• Quenard F, Fournier PE, Drancourt M, Brouqui P. Role of second-line injectable antituberculosis drugs in the treatment of MDR/XDR tuberculosis. Int J Antimicrob Agents. 2017;50(2):252–254. doi:10.1016/j.ijantimicag.2017.01.04228595939
   PubMed Web of Science ®Google Scholar
• Bureau of Statistics of Guizhou. Guizhou Statistical Yearbook; 2018 Available from: http://42.123.101.206:81/tjnj/2018/zk/indexch.htm. Accessed 913, 2019
   Google Scholar
• Yang YB, Xu L, Li L Analysis of influencing factors on non-enrolment treatment of MDR-TB cases in Yunnan province. The 10th International Conference on Public Health Among Greater Mekong Sub-region Countries –Health Equity and Response to Crisis 11; 2018; Kumming, China.
   Google Scholar
• Hutchison C, Khan MS, Yoong J, Lin X, Coker RJ. Financial barriers and coping strategies: a qualitative study of accessing multidrug-resistant tuberculosis and tuberculosis care in Yunnan, China. BMC Public Health. 2017;17:221. doi:10.1186/s12889-017-4089-y28222724
   PubMed Web of Science ®Google Scholar
• Deshmukh RD, Dhande DJ, Sachdeva KS, Sreenivas AN, Kumar AMV, Parmar M. Social support a key factor for adherence to multidrug-resistant tuberculosis treatment. Indian Tuberc. 2018;65(1):41–47. doi:10.1016/j.ijtb.2017.08.030
   PubMedGoogle Scholar
• Mekonnen HS, Azagew AW. Non-adherence to anti-tuberculosis treatment, reasons and associated factors among TB patients attending at Gondar town health centers, Northwest Ethiopia. BMC Res Notes. 2018;11:691. doi:10.1186/s13104-018-3789-430285907
   PubMedGoogle Scholar
• Mulu Fentie A, Tadesse F, Engidawork E, Gebremedhin A. Prevalence and determinants of non-adherence to Imatinib in the first 3-months treatment among newly diagnosed Ethiopian’s with chronic myeloid leukemia. PLoS One. 2019;14(3):e0213557.30845227
   PubMed Web of Science ®Google Scholar
• World Health Organization. Adherence to Long-term Therapies: Evidence for Action. Geneva, Switzerland: WHO; 2003.
   Google Scholar
• Alomar MJ. Factors affecting the development of adverse drug reactions (review article). Saudi Pharm J. 2014;22(2):83–94. doi:10.1016/j.jsps.2013.02.00324648818
   PubMed Web of Science ®Google Scholar
• Wang YY, Liabsuetrakul T, Chongsuvivatwong V, et al. Under- and over-consumption intermittent TB treatment among rural TB patients in south-west China. Int J Tuberc Lung Dis. 2007;11(12):1345–1351: 7.18034957
   PubMed Web of Science ®Google Scholar
• Martelli G, Antonucci R, Mukurasi A, Zepherine H, Nöstlinger C. Adherence to antiretroviral treatment among children and adolescents in Tanzania: comparison between pill count and viral load outcomes in a rural context of Mwanza region. PLoS One. 2019;14(3):e0214014. doi:10.1371/journal.pone.021401430897131
   PubMed Web of Science ®Google Scholar